> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Gilead sNDA for Descovy
- URL: https://www.fdaweb.com/panel-to-review-gilead-snda-for-descovy/
- Published: 2019-06-21T12:00:00.000Z
- Updated: 2026-09-15T01:34:12.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144400

*Federal Register* notice: FDA has announced an 8/7 Antimicrobial Drugs Advisory Committee meeting to discuss a Gilead Sciences supplemental NDA for Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg tablets) and its use for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection among individuals who are HIV-negative and at risk for HIV. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-13355.pdf?ref=fdaweb.com).